出处
《中华内科杂志》
CAS
CSCD
北大核心
2006年第4期344-346,共3页
Chinese Journal of Internal Medicine
基金
国家自然科学基金资助项目(30300312
30470742)
参考文献21
-
1Olsson M,Bruhns P,Frazier WA,et al.Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia.Blood,2005,105:3577-3582.
-
2Jin F,Balthasar JP.Mechanisms of Intravenous immunoglobulin action in immune thrombocytopenic purpura.Hum Immunol,2005,66:403-410.
-
3Cooper N,Heddle NM,Haas M,et al.Intravenous (Ⅳ) anti-D and Ⅳ immunoglobulin achieve acute platelet increase by different mechanisms:modulation of cytokine and platelet responses to Ⅳ anti-D by FcgammaRⅡa and FcgammaRⅢa polymorphisms.Br J Haematol,2004,124:511-518.
-
4Song S,Crow AR,Freedman J,et al.Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP:alternative to IVIG.Blood,2003,101:3708-3713.
-
5Stasi R,Pagano A,Stipa E,et al.Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.Blood,2001,98:952-957.
-
6Braendstrup P,Bjerrum OW,Nielsen OJ,et al.Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.Am J Hematol,2005,78:275-280.
-
7McMillan R,Wang L,Tomer A,et al.Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.Blood,2004,103:1364-1369.
-
8Bussel JB,George JN,Kuter DJ,et al.An open-label,dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG 531) in thrombocytopenic adult patients with immune thrombocytopenic purpura.Blood,2003,102:86a.
-
9赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量:104
-
10Kuwana M,Kaburaki J,Ikeda Y.Autoreactive T cells to platelet GPⅡ b/Ⅲa in immune thrombocytopenic purpura:role in production of anti-platelet autoantibody.J Clin Invest,1998,102:1393-1402.
二级参考文献12
-
1Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol,1996, 93:704-706.
-
2Usuki K, Tahara T, Iki S, et al. Serum thrombopoietin level in various hematological diseases. Stem Cells, 1996, 14:558-565.
-
3yon dem Borne A, Folman C, van den Oudenrijn S, et al. The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. Blood Rev, 2002, 16:57-59.
-
4British Committee for Standerds in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol, 2003,120,574-596.
-
5Stasi R, Brunetti M, Pagano A, et al. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis, 2000, 26:582-586.
-
6Wali YA, AL Lamki, Shah W, et al. Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol, 2002, 19:329-335.
-
7Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-Dose dexamethasone. N Engl J Med, 2003,349: 831-836.
-
8张源慧.特发性血小板减少性紫癜[A].见:张之南 沈悌 主编.血液病诊断及疗效标准 第2版[C].北京:科学出版社,1998.279-285.
-
9廖小梅,唐雪梅,邓承祺,牛挺,孟文彤.血小板生成素和白细胞介素-11对慢性特发性血小板减少性紫癜巨核细胞的影响[J].华西医科大学学报,2001,32(4):572-575. 被引量:16
-
10李蔚,侯明,张茂宏,朱媛媛,马道新.自身免疫性血小板减少性紫癜的特异性免疫学诊断的研究[J].中华血液学杂志,2001,22(7):374-376. 被引量:39
共引文献146
-
1何光毅.地塞米松冲击治疗慢性特发性血小板减少性紫癜29例临床分析[J].四川省卫生管理干部学院学报,2008,27(3):174-175.
-
2时峰.难治性特发性血小板减少性紫癜的治疗进展[J].疑难病杂志,2006,5(5):395-397. 被引量:3
-
3姚庆民,侯明.大剂量地塞米松治疗特发性血小板减少性紫癜10年回顾[J].中华内科杂志,2006,45(10):871-872. 被引量:4
-
4闫振宇,赵永强.难治性特发性血小板减少性紫癜的诊断及治疗[J].内科急危重症杂志,2006,12(6):252-254. 被引量:8
-
5方峻,宋善俊.血液病相关出血的诊断与处理进展[J].医学新知,2006,16(6):365-368. 被引量:1
-
6刘传才,陈琦.血小板生成素的临床应用研究进展[J].贵州医药,2006,30(11):1050-1052. 被引量:4
-
7陈小林,赖应昌,冯秀娟,陈万宁,祁妙华,姜义荣,刘扶兴.大剂量地塞米松治疗慢性特发性血小板减少性紫癜的临床研究[J].临床血液学杂志,2007,20(1):46-47. 被引量:14
-
8刘卿雪.特发性血小板减少性紫癜的治疗体会[J].医学理论与实践,2007,20(8):910-911.
-
9杨仁池.特发性血小板减少性紫癜治疗中应该注意的几个问题[J].国际输血及血液学杂志,2007,30(6):484-486. 被引量:9
-
10刘一,吕欣,董振香.重组人血小板生成素的药理作用和临床评价[J].中国新药杂志,2008,17(3):254-258. 被引量:20
同被引文献20
-
1赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量:104
-
2Rovers MM,Schilder AG,Zielhuis GA,Rosenfeld RM,张江平,杨妙丽,张全安.中耳炎[J].国外医学(耳鼻咽喉科学分册),2005,29(3):141-143. 被引量:442
-
3Wang-gangZHANG,LeiJI,Xing-meiCAO,Yin-xiaCHEN,Ai-liHE,JieLIU,Wan-hongZHAO,San-pengZOU.Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura[J].Acta Pharmacologica Sinica,2005,26(5):598-602. 被引量:8
-
4梁欣荃,王志华,祝平安.干扰素治疗难治性特发性血小板减少性紫癜疗效观察[J].中国医师杂志,2005,7(5):703-704. 被引量:4
-
5姚红霞,吴巨峰,林丽娥,王谷云,符祥俊.难治性特发性血小板减少性紫癜治疗的探讨[J].血栓与止血学,2005,11(6):269-270. 被引量:1
-
6王军,胡玉莲,王西阁,冯建飞,汤有才.特发性血小板减少性紫癜患儿sCD40配体及其mRNA表达水平的变化[J].中华血液学杂志,2006,27(5):348-349. 被引量:4
-
7胡亚美主编.诸福棠实用儿科学[M].7版.北京:人民卫生出版社,2004,1080-1086.
-
8Yamamoto F, Narimatsu H, Ito M, et al. Prediction of clinical outcome in patients with idiopathic thrombocytopenic purpura by evaluating bone marrow clot CD20 ^+ B lymphocytes and morphological changes of megakaryocytes [ J ]. J Clin Exp He matop, 2008,48 ( 1 ) : 11 - 15.
-
9Nakayamada S, Saito K, Nakano K, et al. Activation signal transduction by β1 integrin in T cells from patients with systemic lupus erythematosus [ J]. Arthritis Rheum,2007,56(5 ) : 1559 - 1568.
-
10Murugaiyan G, Martin S, Saha B. Levels of CD40 expression on dendritic cells dictate tumour growth or regression [ J ]. Clin Exp Immurtol, 2007, 149 ( 1 ) : 194 - 202.
引证文献2
-
1王珍(综述),袁晓军(审校),顾龙君(审校).儿童难治性特发性血小板减少性紫癜的治疗进展[J].国际儿科学杂志,2009,36(1):69-71. 被引量:7
-
2邓彩艳,王军,王西阁,冯建飞,张彦洁.特发性血小板减少性紫癜患儿骨髓单个核细胞CD_(40)/CD_(40)L表达的意义[J].实用儿科临床杂志,2009,24(15):1169-1171. 被引量:4
二级引证文献11
-
1李晓红,盛光耀,王春美.血小板三项参数在特发性血小板减少性紫癜和再生障碍性贫血患儿中的表达及意义[J].实用儿科临床杂志,2009,24(21):1694-1695. 被引量:6
-
2金呈强,董海新,刘仿,宋丽,赵元明,孙传祥,高岩,高东田,盛蕊.急性特发性血小板减少性紫癜患儿外周血血小板相关抗体和白细胞介素18的检测[J].新乡医学院学报,2010,27(1):48-51. 被引量:16
-
3陈曦,王文江,刘娟,汪辉,王京华.联合检测PAIg与CD41+淋巴样小巨核对ITP及MDS鉴别诊断的意义[J].现代生物医学进展,2010,10(14):2652-2655. 被引量:2
-
4古学奎,丘和明.分期辨治难治性原发性血小板减少性紫癜57例疗效观察[J].新中医,2010,42(9):68-69. 被引量:7
-
5徐云云(综述),金润铭(审校).儿童难治性特发性血小板减少性紫癜的诊疗进展[J].国际儿科学杂志,2012,39(3):254-257. 被引量:5
-
6李然然(综述),韩波(审校).CD40-CD40配体与儿科疾病[J].国际儿科学杂志,2013,40(1):80-83. 被引量:2
-
7陈影,余燕红,陈少君,易燕桃.地塞米松联合丙种球蛋白治疗小儿急性特发性血小板减少性紫癜的效果观察[J].中国当代医药,2014,21(8):89-90. 被引量:3
-
8覃黄正.不同剂量丙种球蛋白联合地塞米松治疗小儿特发性血小板减少性紫癜的临床疗效分析[J].中国医药科学,2014,4(21):90-92. 被引量:19
-
9杨玉湘.亚标准剂量丙种球蛋白联合地塞米松治疗儿童特发性血小板减少性紫癜的临床研究[J].四川医学,2015,36(7):1026-1028. 被引量:16
-
10吴晓芳,李建琴,胡绍燕,王兆钺,戴兰,毛晨梅,凌婧.miRNA-30a通过介导Th17细胞分化影响免疫性血小板减少性紫癜发病的初步探讨[J].中国实验血液学杂志,2020,28(2):588-594. 被引量:9
-
1郭红荣,韦国桢,俞小卫.机械通气治疗重症支气管哮喘8例临床分析[J].临床肺科杂志,2008,13(2):208-209. 被引量:5
-
2罗显荣,叶小群,王琳,伍伟玲,张丹.机械通气治疗重症支气管哮喘25例[J].中华急诊医学杂志,2002,11(1):52-53. 被引量:8
-
3桂淑玉.支气管哮喘的非常规治疗[J].安徽医科大学学报,1997,32(6):730-731.
-
4夏德发.耐药株伤寒非常规治疗的探讨[J].科技通报,1992,8(2):115-117. 被引量:1
-
5金瑞卿.难治性咯血的非常规治疗[J].中国防痨杂志,1991,13(1):23-24. 被引量:5
-
6李妮妮,张玉东.他汀类药物在慢性心力衰竭患者中的应用现状[J].中国心血管病研究,2008,6(5):394-396. 被引量:8
-
7高亚玥,马一盖.糖皮质激素规律治疗与成人免疫性血小板减少症近期复发的关系[J].中日友好医院学报,2014,28(2):85-88. 被引量:3
-
8李永昌.支气管哮喘的非常规治疗[J].中国社区医师(医学专业),2005,7(19):6-6.
-
9候明.特发性血小板减少性紫癜的定向免疫干预[J].中国实用内科杂志,2008,28(12):1013-1015. 被引量:4
-
10许梅芳,瞿真.艾灸箱联合中医定向透药治疗仪治疗慢性盆腔炎的疗效观察[J].临床合理用药杂志,2015,8(4):91-92. 被引量:9